(MedPage Today) — CHICAGO — Progression-free survival (PFS) in metastatic hormone receptor (HR)-positive breast cancer more than doubled with the AKT inhibitor ipatasertib added to fulvestrant after first-line CDK4/6 inhibition, a randomized…
Source link : https://www.medpagetoday.com/meetingcoverage/asco/115871
Author :
Publish date : 2025-06-03 15:20:00
Copyright for syndicated content belongs to the linked Source.
